fda glp-1 compounding warning september 2025 US clarifies policies on of medicines FDA to Restrict Ingredients Used

The Company is advancing NM-002, a proprietary long-acting GLP-1 agonist into a Phase 2 trial for short bowel syndrome (SBS), a rare, orphan disease, as well as larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease

So what is GHK-Cu peptide used for, in plain terms

The gradual titration approach allows for a personalized adjustment of the Ipamorelin dosage based on your body's response

It allows you to achieve GI while stimulating your bodys GH production, allowing you to be safer and achieve a more equal path toward whatever your objective is compared to using an artificial compound like synthetic HGH